Home / Technology

The platform

Two domains, one fibril, and a composition you can change.

Technology

Self-assembly as the delivery mechanism

A short peptide is cheap to make and easy to change. The problem is that an unfunctionalised peptide is short-lived and weakly binding. Saphtx’s answer is to give each peptide two domains: one that binds the target, and one that drives it to assemble with its neighbours into a fibril.

The fibril is the active object: it presents many binding sites at once, and its composition — which peptides, in what ratio — sets what it presents.

HETERO-PEPTIDES BIND ASSEMBLE BIND ASSEMBLE mixed at a chosen molar ratio β-SHEET FIBRIL VIRUS Many binding sites on one fibril = multivalent attachment
Platform schematic, drawn from the published description.

Properties

Six things that follow from the design

Two domains per peptide

One domain is designed to bind a specific viral protein; the other self-assembles into fibrils. The mix sets the epitope displayed on the surface.

Tunable composition

Fibril binding characteristics are determined by the types of peptides and their molar fractions, so the architecture can be re-pointed at a new target.

Multivalent by design

A fibril presents many binding sites at once, which is how it maintains strong binding to viral protein complexes.

Resilient to mutation

The paper reports that the assembled fibrils retain high resilience to viral mutations.

Small and stable

Self-assembled peptides are about twenty times smaller than antibodies and more stable than unfunctionalised peptides.

Cheap and scalable

The Nature Communications paper describes the platform as efficacious, inexpensive and stable, with excellent tolerability.

Evidence

What has been shown, and how

The antiviral work is published: hetero-peptides self-assembling into β-sheets, tested experimentally and computationally with short peptides that bind the Spike protein of SARS-CoV-2. The paper reports that the fibrils keep enhanced binding to viral protein complexes and remain resilient to viral mutations.

The ocular programme was presented as an abstract at the Biomaterials Society in 2019, and is described on this site as a proposed solution rather than a completed trial.

Work with us

Protein-based therapeutics, translated

Saphtx works with academic inventors to translate engineered proteins toward the clinic. If you would like to work with the company, its inbox is public.